Peter Svennilson net worth and biography

Peter Svennilson Biography and Net Worth

Peter Svennilson founded The Column Group in 2007 and has worked in venture capital and finance for over 35 years. He was the Chairman of Aragon Pharmaceuticals from startup until it was sold to Johnson & Johnson in 2013 and was the Chairman of Seragon Pharmaceuticals until it was sold to Genentech/ Roche in 2014. Mr. Svennilson was a Board Director of NGM Biopharmaceuticals (“NGM” on NASDAQ) and Constellation Pharmaceuticals (“CNST” on NASDAQ). He was also a Board Observer of Arcus Biosciences until the company went public in 2018 (“RCUS” on NYSE).

Prior to TCG, he was the Founder and Managing Partner of Three Crowns Capital where he helped finance large parts of the venture capital for biotech companies such as Tularik, Rosetta, PTC, Chemocentryx, Rinat, Tercica, Somalogic, Infinity and Fiveprime. Prior to Three Crowns Capital he was the Associate Managing Director in charge of European Investment Banking Origination at Nomura in London. Mr. Svennilson is a Trustee at The Institute for Advanced Study in Princeton, New Jersey. Mr. Svennilson received an M.B.A. from the Stockholm School of Economics and Finance.

What is Peter Svennilson's net worth?: The estimated net worth of Peter Svennilson is at least $727,420.66 as of April 26th, 2021. Mr. Svennilson owns 20,302 shares of Revolution Medicines stock worth more than $727,421 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Svennilson may own. Learn More about Peter Svennilson's net worth.
How do I contact Peter Svennilson?: The corporate mailing address for Mr. Svennilson and other Revolution Medicines executives is 700 Saginaw Drive, Redwood City CA, 94063. Revolution Medicines can also be reached via phone at 650-481-6801 and via email at [email protected]. Learn More on Peter Svennilson's contact information.
Has Peter Svennilson been buying or selling shares of Revolution Medicines?: Peter Svennilson has not been actively trading shares of Revolution Medicines over the course of the past ninety days. Most recently, Peter Svennilson sold 100 shares of the business's stock in a transaction on Wednesday, April 28th. The shares were sold at an average price of $42.50, for a transaction totalling $4,250.00. Following the completion of the sale, the director now directly owns 20,302 shares of the company's stock, valued at $862,835. Learn More on Peter Svennilson's trading history.
Who are Revolution Medicines' active insiders?: Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?: In the last twelve months, insiders at the sold shares 34 times. They sold a total of 236,176 shares worth more than $7,455,013.90. The most recent insider tranaction occured on April, 10th when Director Sushil Patel sold 2,155 shares worth more than $79,735.00. Insiders at Revolution Medicines own 8.5% of the company. Learn More about insider trades at Revolution Medicines.
Information on this page was last updated on 4/10/2024.

Peter Svennilson Insider Trading History at Revolution Medicines

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/28/2021	Sell	100	$42.50	$4,250.00	20,302
4/26/2021	Sell	52,984	$42.85	$2,270,364.40	20,302
4/9/2021	Sell	24,701	$43.83	$1,082,644.83	20,302
4/7/2021	Sell	27,953	$45.60	$1,274,656.80	20,302
4/5/2021	Sell	18,215	$46.65	$849,729.75	20,302

Peter Svennilson Buying and Selling Activity at Revolution Medicines

Revolution Medicines Company Overview

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Today's Range

Now: $35.05

$34.84

$36.37

50 Day Range

MA: $31.61

$29.00

$37.41

2 Week Range

Now: $35.05

$15.44

$38.73

Volume

201,487 shs

Average Volume

1,372,451 shs

Market Capitalization

$5.77 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Healthcare Takes A Big Step Forward With The Help Of AI

From The Bull Report | Ad

The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.

Click here to see why this small company is trusted by the Mayo Clinic